Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;68(1):51-55.
doi: 10.1007/s11686-022-00632-3. Epub 2022 Nov 8.

In Vitro Determination of Antileshmanial Activities of Benzimidazolium Derivatives on L. major Promastigotes and Amastigotes

Kübra Kelleci  1   2 , Eda Gölebatmaz  3
Affiliations

In Vitro Determination of Antileshmanial Activities of Benzimidazolium Derivatives on L. major Promastigotes and Amastigotes

Kübra Kelleci et al. Acta Parasitol. 2023 Mar.

Abstract

Purpose: Leishmaniasis is a serious public health problem infecting millions of people worldwide. An effective and reliable treatment method to be used in the treatment of the disease has not been developed yet.

Methods: In this article, the anti-leishmanial activities of two benzimidazolium derivatives (B.A and B.B) against Leishmania major promastigotes and amastigotes, which are known to cause cutaneous leishmaniasis, were investigated for the first time. The immunostimulatory activity of the developed formulations was determined using the J774 murine macrophage cell line.

Results: B.A and B.B compounds were found to have a much higher cytotoxic effect than Amphotericin B (IC50 value 0.75 μM ± 0.03), which is used as the reference drug. The IC50 value was determined as 2.02 µM ± 0.52 for B.A and 1.83 µM ± 0.71 for B.B in Leishmania promastigotes. In addition, IC50 values of B. A and B.B Leishmania amastigotes were found to be 1.01 µM and 0.67 µM, respectively. It was found that B.B was 81.12 times more selective than Amphotericin B and showed the highest selectivity against L. major promastigotes (359.09) and amastigotes (980.80). Considering the selectivity indices (SI) of B.A and B.B, both compounds tested are more promising than Amphotericin B.

Conclusion: The results showed that benzimidazolium derivatives have anti-leishmanial potential against L. major, which is the causative agent of cutaneous leishmaniasis. Thus, we can say that the obtained results will help the development of effective and safe antileishmanial drug formulations against cutaneous leishmaniasis.

Keywords: Benzimidazolium; Cutaneous Leishmaniasis; Leishmania major.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization (2010) Control of the leishmaniasis WHO technical report series 949. World Health Organization, Geneva, Switzerland
    1. Ikeogu NM, Akaluka GN, Edechi CA, Salako ES, Onyilagha C, Barazandeh AF, Uzonna JE (2020) Leishmania immunity: advancing immunotherapy and vaccine development. Microorganisms 8(8):1201. https://doi.org/10.3390/microorganisms8081201 - DOI - PubMed - PMC
    1. Tahlan S, Kumar S, Kakkar S, Narasimhan B (2019) Benzimidazole scaffolds as promising antiproliferative agents: a review. BMC chem 13(1):1–16. https://doi.org/10.1186/s13065-019-0579-6 - DOI
    1. Marinescu M (2021) Synthesis of antimicrobial benzimidazole–pyrazole compounds and their biological activities. Antibiotics 10(8):1002. https://doi.org/10.3390/antibiotics10081002 - DOI - PubMed - PMC
    1. Aragón-Muriel A, Liscano Y, Upegui Y, Robledo SM, Ramírez-Apan MT, Morales-Morales D, Polo-Cerón D (2021) In Vitro evaluation of the potential pharmacological activity and molecular targets of new benzimidazole-based schiff base metal complexes. Antibiotics 10(6):728. https://doi.org/10.3390/antibiotics10060728 - DOI - PubMed - PMC

LinkOut - more resources